Eesti - eesti - Ravimiamet

actavis group hf - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 50mg 1tk; 5mg 1ml 100mg 1tk

Eesti - eesti - Ravimiamet

kalceks as - ondansetroon - süste-/infusioonilahus - 2mg 1ml 2ml 25tk; 2mg 1ml 2ml 10tk; 2mg 1ml 2ml 5tk; 2mg 1ml 4ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.